Patents by Inventor Mark Giangiordano

Mark Giangiordano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines
    Publication number: 20030069246
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: February 25, 2002
    Publication date: April 10, 2003
    Applicant: Neurogen Corporation
    Inventors: James W. Darrow, Stephane J. De Lombaert, Charles A. Blum, Jennifer N. Tran, Mark A. Giangiordano, David Andrew Griffith, Philip Albert Carpino
  • Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
    Patent number: 6476038
    Abstract: Disclosed are compounds of the formula: where R1, R2, R3, R4, R5, R6, and X are defined herein. These compounds are selective modulators of NPY1 receptors. These compounds are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of NPY1 receptors and as standards in assays for NPY1 receptor binding. Methods of using the compounds in receptor localization studies are given.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: November 5, 2002
    Assignees: Neurogen Corporation, Pfizer Inc.
    Inventors: James W. Darrow, Stéphane De Lombaert, Charles Blum, Jennifer Tran, Mark Giangiordano, David Andrew Griffith, Philip Albert Carpino
  • Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
    Patent number: 6372743
    Abstract: Disclosed are compounds of the formula: where R1, R2, R3, R4, R5, R6, and X are defined herein. These compounds are selective modulators of NPY1 receptors. These compounds are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of NPY1 receptors and as standards in assays for NPY1 receptor binding. Methods of using the compounds in receptor localization studies are given.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: April 16, 2002
    Assignees: Neurogen Corporation, Pfizer Inc.
    Inventors: James W. Darrow, Stephane De Lombaert, Charles Blum, Jennifer Tran, Mark Giangiordano, David Andrew Griffith, Philip Albert Carpino